Epirubicin PhaRes 2 mg/ml iv infusion
Generic: Epirubicin Hydrochloride
Company: ZAS Corporation. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated October 14, 2025.
Generic: Epirubicin Hydrochloride
Company: ZAS Corporation. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated October 14, 2025.
Sorted by price per iv infusion. Ask your pharmacist before you switch brands.
Prices as listed on BestinMeds.
No price is listed for this strength yet.
Advertisement
What this medicine is for, how to take it, and what to watch for.
Read the full Epirubicin Hydrochloride guide
Stomach carcinoma Epirubicin Injection is an anthracycline topoisomerase II inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer
Acute leukaemias; Lymphoma; Multiple myeloma; Solid tumours: As a single agent: 60-90 mg/m2 3-4 wkly. Max (total cumulative dose): 0.9-1 g/m2. Palliative care: 12.5-25 mg/m2 once wkly. Adjuvant treatment in axillary-node positive breast cancer: Recommended starting doses: 100-120 mg/m2 as a single dose on day 1 or as 2 divided doses on days 1 and 8 of each 28-day cycle. Repeat for 6 cycles. Intravesical Local treatment of bladder carcinoma: As 0.1% soln: 50 mg/wk for 8 wk; reduce dose if chemical cystitis develops. For carcinoma in-situ: 80 mg in 50 mL wkly. For prevention of recurrence in patients who have undergone transurethral resection: 50 mg/wk for 4 wk, followed by 50 mg/mth for 11 mth; retain soln in the bladder for 1 hr during each administration.
In early breast cancer, acute adverse events occurring in ≥10% of patients are leucopenia, neutropenia, anemia, thrombocytopenia, amenhorrhea, lethargy, nausea/vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, local toxicity and rash/itch. Long term adverse events occurring at a frequency of 1-2% are asymptomatic drops in LVEF and CHF and secondary leukemia.
Previous extensive radiotherapy, bone infiltration by tumour, severe renal and hepatic dysfunction. May cause tumor lysis syndrome or radiation recall. Elderly women >70 yr. CV disease, hypertensive cardiomyopathy; monitor hematological and cardiac function regularly. Extravasation during IV admin may result in severe local tissue necrosis. Do not give via IM/SC routes as extravasation can lead to severe local necrosis
Discontinue nursing prior to taking Epirubicin. Not known if excreted in breast milk
Epirubicin, an anthracycline with cytotoxic properties. It inhibits DNA and RNA synthesis by steric obstruction after intercalating between DNA base pairs that triggers DNA cleavage by by topoisomerase II. It also inhibits DNA helicase and generates cytotoxic free radicals.
Paclitaxel and other anthracyclines. Cimetidine, heparin. Antineoplastic drugs, cardiotoxic drugs, radiation, hepatoactive drugs.
This information is not available. Ask your doctor or pharmacist.
This information is not available. Ask your doctor or pharmacist.
Cytotoxic Chemotherapy
This information is not available. Ask your doctor or pharmacist.
BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.
Advertisement
Generic: Epirubicin Hydrochloride
783.06taka / 10 mg vial
View medicineGeneric: Epirubicin Hydrochloride
1420.00taka / 10 mg vial
View medicineAdvertisement